- Pin
- What are the Gate Post Community Growth Points? Learn how it works and what rewards you can get! 👇
- 👀 #GateCryptoGiveaway# - Whose eyes are these?
Memecoin Quiz: Guess the memecoins based on the eyes below!
💰 $10 Points * 4 winners
To join:
1️⃣ Follow Gate_Post
2️⃣ Like this post
3️⃣ Drop your answer in the comments
📅 Ends at 04:00 AM, Jun 7 (UTC)
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.